AAPL vs BBIO Stock Comparison

AAPL currently leads BBIO in this stock comparison, with AIQ scores of 73 vs 64. The clearest difference is risk resilience.

Market data as of Nov 15, 2026 market close· AIQ score gap 9 points
AAPL
Technology
vs
BBIO
Healthcare
AAPL
Apple Inc.
Leads
Price
$356
Day move
+0.39%
AIQ Score
73/100
Best edge
Risk Resilience
Sector
Technology
BBIO
BridgeBio Pharma, Inc.
Price
$78.30
Day move
+0.17%
AIQ Score
64/100
Best edge
Balanced
Sector
Healthcare

What is the main difference between AAPL and BBIO?

AAPL leads the current stock comparison as Apple Inc., with the clearest separation coming from risk resilience and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Apple Inc. vs BridgeBio Pharma, Inc.

Data as of Nov 15, 2026· market close· Cross-sector · Technology vs Healthcare· Coverage 65/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 4/10

AAPL leads

AAPL leads by 9 AIQ points, primarily on Risk Resilience and Momentum, but the lead has narrowed from 24 points over 30 sessions. Wall Street currently favors BBIO on target upside.

Fragile: 3 of 6 evidence groups support AAPL, its lead is narrowing, and its signal state is cleanly positive.

Evidence agreement: 3 of 6Comparison trend: Weakening
AAPL

Apple Inc.

Leads
AIQ Score
73/100
AIQ Edge Score
10/10
BBIO

BridgeBio Pharma, Inc.

AIQ Score
64/100
AIQ Edge Score
7/10

The Algovestiq AIQ Score currently favors AAPL over BBIO, 73 versus 64 as of Nov 15, 2026. AAPL's advantage is driven primarily by stronger risk resilience and momentum. AAPL also shows the weaker technical structure relative to its 50-day moving average, though analyst target upside currently favors BBIO. 3 of 6 covered evidence groups favor AAPL today, and the comparison is rated Fragile on stability: only 3 of 6 covered evidence groups agree. AAPL lead: Weakening — the AIQ differential moved from 24 to 9 points over 30 sessions.

Compare Apple Inc. and BridgeBio Pharma, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

AAPL
+137.8%
BBIO
+69.8%

Total return comparison

Growth of $10,000, distributions reinvested

AAPL $23,779 · BBIO $16,985

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare AAPL and BBIO against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

AAPL advantage
0
BBIO advantage
  • Risk Resilience82 vs 62
    AAPL +20
  • Momentum83 vs 69
    AAPL +14
  • Quality69 vs 66
    Even
  • Value56 vs 55
    Even

3 of 6 evidence groups favor AAPL. AAPL’s edge is concentrated in risk resilience and momentum.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

AAPL-1 AIQ

Largest factor move: Value -1

No signal started or stopped since the prior session; its 7 active signals are unchanged.

BBIO+1 AIQ

Largest factor move: Quality +1

No signal started or stopped since the prior session; its 5 active signals are unchanged.

AAPL's lead narrowed by 2 AIQ points in the latest session.

Deeper signal detail for each name lives on its own signals page — AAPL and BBIO both carry a full feed there.

The central trade-off

AAPL (Apple Inc.): the stronger current systematic profile, led by risk resilience and momentum.

BBIO (BridgeBio Pharma, Inc.): the counter-case, on fundamentals, analyst expectations — but at materially higher volatility, 39.1% against 27.9%.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

AAPL

AAPL on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

BBIO

BBIO on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

AAPL

AAPL on the Momentum factor, by 14 points.

Lower downside

AAPL

AAPL on Risk Resilience, by 20 points.

Analyst upside

BBIO

BBIO on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors AAPL, analyst targets favor BBIO. That disagreement is the most useful thing on this page.

MeasureAAPLBBIONote
Implied upside to target-1.3%+42%BBIO has more room
Target dispersion+33.3%+62.1%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering4622Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 6 covered evidence groups favor AAPL. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreAAPL73 vs 64
FundamentalsBBIOon balancerevenue growth 4.6% vs 44.9%; EPS growth 3.9% vs 46.2%; TTM ROE 27.4% vs 3.4%; gross margin 48.8% vs 93.5%; operating margin 33% vs -43.4% — BBIO takes 3 of 5 decided legs, not all of them
ValuationEvenValue 56 vs 55
TechnicalsAAPLPrice vs 50-day 5.1% vs 11.9%; vs 200-day 18.3% vs 7.7%
Risk ResilienceAAPLRisk Resilience 82 vs 62
Analyst expectationsBBIOTarget upside -1.3% vs 42%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AAPL and BBIO and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is moderate at 9 points.
  • Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The leader's signal state is cleanly positive. (supports the conclusion holding)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on AAPL.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

AAPL lead: Weakening — the AIQ differential moved from 24 to 9 points over 30 sessions.

May 27AAPL leads above the line · BBIO leads belowNov 13
Today
AAPL +9
73 vs 64
7 sessions ago
AAPL +12
74 vs 62
30 sessions ago
AAPL +24
74 vs 50
90 sessions ago
AAPL +12
71 vs 59

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

AAPL

6 bullish / 0 bearish / 1 neutral

Only AAPL

  • Bollinger Band Squeeze — neutral, volatility, short horizon (6.9%)
  • Golden Cross Active — bullish, trend, long horizon (12.54%)
  • 52-Week High Proximity — bullish, risk_regime, long horizon (0.0%)
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
  • Uptrend Structure Active — bullish, trend, long horizon
BBIOConflicted

2 bullish / 2 bearish / 1 neutral, conflicted

Only BBIO

  • Death Cross Active — bearish, trend, long horizon (3.88%)
  • ADX Trend Strengthening — neutral, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.38x)

Both carry 2 more signals that do not separate them: EMA Ribbon Expansion Bullish, TRIX Bullish Signal.

BBIO is conflicted, so the timing case there is weaker than the score alone suggests.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

AAPLDivergence

Price is up while the AIQ Score moved down 1 points over the same session — price and model disagree (price +0.39%, AIQ -1 points).

BBIOConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +0.17%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1BBIO closes the Risk Resilience gap — currently 20 points behind, the largest single contributor to AAPL's edge.
  2. 2BBIO's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3AAPL's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
  4. 4The narrowing continues — the lead has already given back 15 points over 30 sessions, and a further 9-point move would eliminate AAPL's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

BBIO leads on balance
MetricAAPLBBIO
Revenue growth (YoY)4.6%44.9%
EPS growth (YoY)3.9%46.2%
Gross margin48.8%93.5%
Operating margin33%-43.4%
Return on equity (TTM)27.4%3.4%
Debt to equity0.71-1.5

Performance

AAPL leads 4 of 6 windows
MetricAAPLBBIO
1 week (5 sessions)4.1%5.4%
1 month (20 sessions)3.7%17.9%
3 months (63 sessions)16.6%-2%
6 months (126 sessions)18.7%18.4%
Year to date31%2.4%
1 year (252 sessions)30.3%18.2%

Technicals

AAPL has the stronger structure
MetricAAPLBBIO
RSI (14)60.665
ADX (14)18.738.9
Price vs 50-day5.1%11.9%
Price vs 200-day18.3%7.7%
Volatility (1M, annualized)27.9%39.1%

Risk

AAPL is the more resilient
MetricAAPLBBIO
Beta0.620.95
Sharpe ratio1.040.55
Sortino ratio1.520.84
Max drawdown-13.8%-29.8%
Current drawdown0%-13.2%
Annualized volatility24.9%44.1%
Value at risk (95%)-2%-4%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, AAPL or BBIO?

On the Algovestiq AIQ Score, AAPL is the stronger of the two as of Nov 15, 2026, scoring 73 against BBIO's 64. The edge comes from risk resilience and momentum. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is AAPL or BBIO the better buy right now?

AAPL carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 3 of 6 covered evidence groups agree. Treat the lead as provisional.

Why does the AIQ Score favor AAPL over BBIO?

The composite weights Quality, Value, Momentum and Risk Resilience. AAPL leads Risk Resilience by 20 points; AAPL leads Momentum by 14 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, AAPL or BBIO?

Analyst price targets imply -1.3% upside for AAPL and +42% for BBIO, so the Street currently favors BBIO. That points the opposite way to the AIQ Score, which favors AAPL. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, AAPL or BBIO?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, AAPL or BBIO?

BBIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, AAPL or BBIO?

AAPL on the Momentum factor, by 14 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, AAPL or BBIO?

AAPL is the more resilient of the two, so the other name carries the higher downside risk. AAPL on Risk Resilience, by 20 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is AAPL more profitable than BBIO?

The profitability evidence is mixed: gross margin 48.8% vs 93.5%; operating margin 33% vs -43.4%; ttm roe 27.4% vs 3.4%. AAPL leads on two measures and BBIO on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is AAPL's lead over BBIO getting stronger or weaker?

AAPL lead: Weakening — the AIQ differential moved from 24 to 9 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the AAPL vs BBIO verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BBIO closes the Risk Resilience gap — currently 20 points behind, the largest single contributor to AAPL's edge; BBIO's Death Cross Active resolves — a bearish trend rule currently active against it; AAPL's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; the narrowing continues — the lead has already given back 15 points over 30 sessions, and a further 9-point move would eliminate AAPL's advantage entirely.

What do the current signals say about AAPL and BBIO?

AAPL: 6 bullish / 0 bearish / 1 neutral. BBIO: 2 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AAPL is Golden Cross Active (bullish, long horizon). On BBIO it is Death Cross Active (bearish, long horizon).

Compare AAPL and BBIO with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.